联合临床与Delta影像组学特征的两阶段模型预测高级别胶质瘤放化疗后预后
该回顾性双中心研究纳入143例接受标准化放化疗的高级别胶质瘤患者,提取放疗前及放疗中MRI影像组学特征并计算Delta特征,结合临床变量构建随机生存森林模型预测总生存。联合模型在验证集和外部测试集的C-index分别为0.818和0.761,外部测试集12、18、24、30个月OS的AUC分别为0.842、0.856、0.796、0.943,Kaplan-Meier分析显示显著风险分层(p=0.002)。
要点
- 联合临床变量与Delta影像组学特征的两阶段模型可提升HGG放化疗后OS预测效能。
- 外部测试集12–30个月OS的AUC为0.796–0.943,Kaplan-Meier风险分层显著(p=0.002)。
- 外部验证集样本量有限(n=27)且主模型未纳入MGMT启动子甲基化状态,结果需前瞻性验证。
核心结论
- 整合多时间点影像组学、Delta影像组学特征与临床变量可能有助于预测HGG患者标准化放化疗后的总生存。
研究设计与样本
- 回顾性双中心研究,共纳入143例接受标准化放化疗的高级别胶质瘤患者。
- 训练队列116例(行5折交叉验证),外部测试队列27例。
- 从放疗前和放疗中MRI扫描提取影像组学特征,Delta特征为两个时间点特征之差。
- 采用基于弹性网的稳定性选择进行特征筛选,并用Cox模型生成各特征集的影像组学评分(Rad-scores)。
- Rad-scores与临床变量结合纳入随机生存森林(RSF)模型预测总生存,并以Kaplan-Meier分析评估预后分层。
诊断标准与关键数值
- 联合临床变量与Delta影像组学的模型在验证集和外部测试集的C-index分别为0.818和0.761,优于仅基于影像组学或仅基于临床特征的模型。
- 外部测试集12、18、24、30个月OS的AUC分别为0.842、0.856、0.796、0.943。
- 外部测试集Kaplan-Meier分析显示显著风险分层(p = 0.002)。
临床应用与阅片要点
- 可参考联合放疗前与放疗中MRI的Delta影像组学特征及临床变量构建模型,用于HGG放化疗后个体化OS预测。
- 报告时需注意外部验证队列仅27例,模型效能尚需更大样本前瞻性验证。
- 主模型未纳入MGMT启动子甲基化状态,解读预测结果时应考虑该分子标志物缺失的影响。
局限性
- 回顾性研究设计。
- 外部验证队列样本量有限(n = 27)。
- 主模型未纳入MGMT启动子甲基化状态。
- 探索性发现需在更大前瞻性队列中进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: This study aims to evaluate the efficacy of integrating pre-radiotherapy and mid-radiotherapy radiomics, temporal changes in tumor radiomics (delta radiomics) during chemoradiotherapy, and clinical variables into prognostic models for individualized overall survival (OS) prediction in patients with high-grade glioma (HGG).
METHODS: A total of 143 patients with HGG who underwent standard chemoradiotherapy were retrospectively enrolled from two centers. Patients were divided into a training cohort (n = 116), in which 5-fold cross-validation was performed, and an external test cohort (n = 27). Radiomics features were extracted from pre-radiotherapy and mid-radiotherapy MRI scans, and delta radiomic features were calculated as the differences between the two timepoints. Feature selection was performed using elastic-net-based stability selection, and radiomics scores (Rad-scores) were generated for each selected feature set using Cox models. Rad-scores were subsequently combined with clinical variables in a random survival forest (RSF) model for OS prediction. Kaplan-Meier survival analysis was performed to evaluate prognostic stratification.
RESULTS: The combined model integrating clinical variables and delta radiomics achieved a C-index of 0.818 and 0.761 in the validation and external test cohorts, respectively, outperforming models based solely on radiomics or clinical features. In the external test cohort, time-dependent discrimination yielded 12-, 18-, 24- and 30-month OS AUCs of 0.842, 0.856, 0.796, and 0.943, and Kaplan-Meier analysis showed significant risk stratification (p = 0.002).
CONCLUSION: The findings of this retrospective study suggest that integrating multi-timepoint radiomics, delta radiomics features, and clinical variables may facilitate OS prediction in patients with HGG following standard chemoradiotherapy. While promising, the exploratory findings require further validation in larger prospective cohorts, given the limited size of the external validation cohort and the absence of MGMT promoter methylation status from the main model.
引用
- Feng Q, Pan M, Lin Y, et al. A two-stage model combining clinical and delta-radiomics features for prognosis in high-grade gliomas after chemoradiotherapy: a retrospective study. Radiol Med. 2026. PMID: 42873435. doi:10.1007/s11547-026-02295-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。